Inovio Pharmaceuticals, Inc. (INO) Citizens JMP Life Sciences Conference (Transcript)

Company Overview - Inovio Pharmaceuticals is on track to potentially have the first DNA immunotherapy approved in the US, distinguishing itself from the more widely recognized mRNA therapies [1] - The company emphasizes the stability of DNA compared to mRNA, which is inherently more unstable and requires lipid nanoparticles for delivery [2] Technology Differentiation - DNA medicines utilize a proprietary delivery system called CELLECTRA, allowing for more stable distribution without the need for ultracold storage, unlike mRNA which requires frozen shipping [2] - The immune responses generated by DNA medicines differ from those of mRNA, with DNA being capable of producing a broader range of immune responses [2]